系统免疫炎症指数对激素受体阴性乳腺癌新辅助化疗后病理完全缓解的预测价值  

Prediction value of systemic immune inflammatory index on pathological complete response in patients with hormone receptor negative breast cancer undergoing neoadjuvant chemotherapy

作　　者：王轩可 程绍强[1] WANG Xuanke;CHENG Shaoqiang(Department of Breast Surgery,Tumor Hospital Affiliated to Harbin Medical University,Heilongjiang Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院乳腺外科,黑龙江哈尔滨150086

出　　处：《现代肿瘤医学》2022年第20期3693-3697,共5页Journal of Modern Oncology

摘　　要：目的:探讨化疗前系统免疫炎症指数(systemic immune-inflammation index, SII)与激素受体阴性乳腺癌新辅助化疗(neoadjuvant chemotherapy, NAC)后病理完全缓解(pathological complete response, pCR)的关系。方法:回顾性分析2013年1月-2017年1月在我院接受新辅助化疗并行手术的278例女性乳腺癌临床病理资料,组间分析通过Pearson’sχ~2进行评估。使用Logistic回归模型进行单因素和多因素分析。结果:本研究共91例(32.7%)患者接受新辅助化疗后获得pCR,其中低SII组55例,高SII组36例,SII与pCR相关(P=0.015)。单因素分析显示:T+T组(pCR率37.10%)较T+T组(pCR率15.79%)更易获得pCR(P=0.003);低SII组(pCR率39.57%)较高SII组(pCR率25.90%)更易获得pCR(P=0.016);将单因素分析中差异具有统计学意义的临床病理特征纳入多因素分析显示:与T+T组相比,T+T组更难获得pCR(P=0.005);与低SII组相比,高SII组更难获得pCR(P=0.031)。结论:SII、临床T分期是乳腺癌新辅助化疗后pCR的独立预测因素,低SII且T+T组患者更易获得pCR。Objective:To investigate the relationship between systemic inflammatory index and pathological complete response of hormone receptor negative breast cancer after neoadjuvant chemotherapy.Methods:The clinicopathological data of 278 female breast cancer patients who received neoadjuvant chemotherapy and surgery from January 2013 to January 2017 in our hospital were retrospectively analysed.The intergroup analysis was evaluated by Pearson’s χ~2,Logistic regression model was used for univariate and multivariate analysis.Results:In this study, 91 patients(32.7%) got pCR after receiving neoadjuvant chemotherapy.Among them, 55 patients were in the low SII group and 36 patients were in the high SII group.SII was related to pCR(P=0.015).Univariate analysis showed that the T+Tgroup(pCR rate 37.10%) was easier to obtain pCR than the T+Tgroup(pCR rate 15.79%)(P=0.003).The low SII group(pCR rate 39.57%) was easier to attain pCR than the higher SII group(pCR rate 25.90%)(P=0.016).The clinical pathological characteristics with statistically significant differences in the univariate analysis were included in the multivariate analysis.Compared with the T+Tgroup, the T+Tgroup was more difficult to obtain pCR(P=0.005).Compared with the low SII group, the high SII group was more difficult to obtain pCR(P=0.031).Conclusion:SII and clinical T stage are independent predictors of pCR after neoadjuvant chemotherapy for breast cancer.Patients with low SII and T+Tgroup are more likely to obtain pCR.

关 键 词：激素受体阴性乳腺癌 新辅助化疗 病理完全缓解 系统免疫炎症指数 

分 类 号：R737.9[医药卫生—肿瘤]